Now, that industry has been transformed into an underregulated business opportunity, through which a multibillion-dollar peptide industry may be about to explode
Medication-based treatments are emerging, with Zepbound being the first approved drug in this category
Q.: How do patients take the drugs
Tirzepatide has the ability to cause stomach upset, loss of appetite, tiredness, and constipation
Puedes consumirla en ayunas o con las comidas, segn tu preferencia
Tirzepatide: Dual GLP-1/GIP Agonist Tirzepatide activates two receptor types simultaneously: GLP-1 (Glucagon-like peptide-1): Slows gastric emptying, reduces appetite, and enhances insulin secretion GIP (Glucose-dependent insulinotropic polypeptide): Improves insulin sensitivity and may have direct effects on fat tissue Retatrutide: Triple GLP-1/GIP/Glucagon Agonist Retatrutide includes everything tirzepatide does, plus a third target: GLP-1: Same appetite suppression and insulin benefits GIP: Same metabolic and insulin sensitizing effects Glucagon receptor: Increases energy expenditure, promotes fat oxidation, and may help preserve lean muscle mass Why Glucagon Matters Glucagon shifts the body toward burning stored fat for energy and increases metabolic rate